Use of mycophenolate in ANCA-associated renal vasculitis: 13 years of experience at a university hospital | Zendy

Juliana Draibe | Zendy; Rafael Poveda | Zendy; Xavier Fulladosa | Zendy; Antonio Vidaller | Zendy; C. Zulberti | Zendy; Montserrat GomàiFreixanet | Zendy; Ramón M. Pujol | Zendy; Èlia Ripoll | Zendy; Joan Torrás | Zendy; J.M. Grinyó | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Use of mycophenolate in ANCA-associated renal vasculitis: 13 years of experience at a university hospital

Author(s) -

Juliana Draibe,

Rafael Poveda,

Xavier Fulladosa,

Antonio Vidaller,

C. Zulberti,

Montserrat GomàiFreixanet,

Ramón M. Pujol,

Èlia Ripoll,

Joan Torrás,

J.M. Grinyó

Publication year - 2015

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfv061

Subject(s) - medicine , anca associated vasculitis , mycophenolate , vasculitis , kidney disease , intensive care medicine , dermatology , transplantation , disease

Standard therapy with corticosteroids (CS) and cyclophosphamide (CYC) followed by azathioprine has been shown to improve renal and patient survival in ANCA-associated renal vasculitis (rAAV). Mycophenolate mofetil (MF) has been progressively introduced for the treatment of rAAV in the last years because of its immunosuppressive efficacy combined with a lower toxicity profile. In this study, we retrospectively analyse the results of the introduction of MF for maintenance and induction therapy in rAAV in our institution from 2001 to 2013.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research